2012 International LAM Research Conference

描述（由申请人提供）：LAM基金会2012年淋巴管平滑肌瘤病国际研究会议将重点关注女性致命性肺部疾病淋巴管平滑肌瘤病（LAM）中发生的平滑肌增殖和囊性肺破坏的分子机制。这是第十三届年度辛辛那提LAM会议，它已经从一个专门的家庭/患者会议发展成为LAM和结节性硬化症的最先进的科学会议。基础科学会议将突出对LAM中平滑肌增殖的细胞和遗传基础的研究，并将重点关注外源性生长因子，性激素，基因突变，淋巴管生成，细胞内信号传导机制和转录调控变化的作用。其他课程将探讨肺平滑肌浸润和肺实质囊性重塑之间的联系，包括LAM细胞对金属蛋白酶和结缔组织基质的阐述。同时进行的临床会议将解决LAM的困难管理问题，包括激素治疗、航空旅行、妊娠、肺移植和胸膜并发症。基础和临床科学轨道已经协调，使所有参与者参加主题会议，并在会议之间自由交通。一个以患者为导向的研讨会将解决175名LAM患者和LAM家庭成员的关键临床问题，预计他们将参加，并将在基础和临床跟踪主席的科学会议总结中达到高潮。在会议的最后一天举行科学圆桌讨论会，以审查会议的主要成果并规划未来的会议。每场会议将由该领域的专家主持，并邀请演讲者以及从提交的摘要库中选出的演讲者。一直有意识地努力吸引来自相关学科的成熟调查人员，他们可以补充现有的LAM调查人员的专业知识。由讨论带头人主持的讨论将是所有会议的重要组成部分。优秀的初级研究人员将获得旅费赠款，并有机会以平台和海报形式展示他们的研究。本次会议的目标是为领先的专家提供一个论坛，讨论LAM的分子和细胞基础，审查LAM的临床管理，介绍前沿研究，整合概念并确定创造性和创新性的研究方向。

DESCRIPTION (provided by applicant): The LAM Foundation 2012 Lymphangioleiomyomatosis International Research Conference will focus on the molecular mechanisms of smooth muscle proliferation and cystic lung destruction that occur in the fatal lung disease of women, Lymphangioleiomyomatosis (LAM). This is the thirteenth annual Cincinnati LAM conference, which has evolved from a dedicated family/patient conference to a state of the art scientific meeting for LAM and tuberous sclerosis. The basic science sessions will highlight research on the cellular and genetic basis of smooth muscle proliferation in LAM, and will focus on the role of exogenous growth factors, sex hormones, genetic mutations, lymphangiogenesis, intracellular signaling mechanisms and changes in transcriptional regulation. Additional sessions will explore the link between smooth muscle infiltration of the lungs and the cystic remodeling of pulmonary parenchyma, including the elaboration of metalloproteinases and connective tissue matrix by LAM cells. Concurrent clinical sessions will address difficult management issues in LAM, including hormonal therapy, air travel, pregnancy, lung transplantation and pleural complications. The Basic and Clinical Science tracks have been coordinated to allow all participants to attend keynote sessions and to traffic freely between sessions. A patient-oriented seminar will address key clinical issues for 175 LAM patients and LAM family members who are expected to attend, and will culminate in a summary of scientific sessions by the Basic and Clinical Track Chairs. A scientific roundtable discussion is held on the last day of the conference to review the key outcomes of the conference and to plan future conferences. Each session will be chaired by an expert in the field and will have invited speakers as well as speakers chosen from the pool of submitted abstracts. There has been a conscious effort to attract established investigators from related disciplines who can complement the expertise of the current pool of LAM investigators. Discussion facilitated by a discussion leader will be an important component of all sessions. Outstanding junior investigators will be awarded travel grants and will be given the opportunity to present their research in platform and poster formats. The goal of this conference is to provide a forum for leading experts to discuss the molecular and cellular basis of LAM, review the clinical management of LAM, to present cutting edge research, to integrate concepts and to identify creative and innovative research directions.